Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo.
Yue Huang, Hui Yin Tan, Jiaqi Yuan...
https://pubmed.ncbi.nlm.nih.gov/39392424/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-13
460
Participants Needed
67
Research Sites
N/A
Total Duration
Researchers are evaluating AZD8205, a new antibody drug conjugate, as a possible treatment for advanced or metastatic solid tumors including breast cancer, biliary tract carcinoma, ovarian cancer, endometrial cancer, and squamous non-small cell lung cancer. This Phase IIIa multi-center, open-label study aims to assess AZD8205 alone or combined with other anti-cancer agents to determine safety, tolerability, dosing, and anti-tumor activity. The study includes multiple sub-studies focusing on different drug combinations and tumor types. Participants may receive AZD8205 as monotherapy or in combination with rilvegostomig, saruparib, and AZD9574. The study has dose escalation phases to identify the recommended phase 2 dose and expansion phases to evaluate anti-tumor effects in selected solid tumors. Some combinations may involve triplet therapies depending on emerging safety data. Treatments will be given according to protocol schedules within each sub-study. Throughout the study, participants will undergo regular monitoring for adverse events, lab tests, ECGs, vital signs, and pharmacokinetic assessments for up to two years. Researchers will measure outcomes such as response rates, duration of response, progression-free survival, overall survival, and immunogenicity. Safety evaluations continue from informed consent to 30 days after the last dose. The study is randomized and open-label, with ongoing assessments during treatment and follow-up periods.
CONDITIONS
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
A
AstraZeneca Clinical Study Information Center
A
AstraZeneca Breast Cancer Study Locator Service
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AZD8205 Regimens (Alone or in Combination) | Current Standard-of-Care Therapy |
|---|---|---|
| What it is | AZD8205-based regimens include an investigational antibody-drug conjugate, studied alone or combined with other novel agents (rilvegostomig, saruparib, AZD9574) in adults with advanced, previously treated solid tumors across multiple cancer types. | Current standard care for advanced/metastatic solid tumors is systemic therapy tailored to cancer type and prior treatment. This can include chemotherapy, immune checkpoint inhibitors, anti-hormonal, or targeted agents as per disease-specific guidelines and prior lines of therapy. |
| Role in trial | Investigational treatment assessed for safety, tolerability, pharmacokinetics, and anti-tumor activity in advanced malignancies after standard options have failed or become unsuitable. | Control of disease and symptoms, and prolonged survival, using guideline-recommended systemic therapies in patients with relapsed or metastatic solid cancers, with selection based on tumor type, prior response, and overall health. |
| Primary use | Being studied for its safety, optimal dosing, and preliminary anti-cancer activity when used alone or in combination in heavily pretreated or refractory advanced solid tumor populations. | Established systemic therapies are used to control cancer progression, manage symptoms, and extend survival in patients whose cancers have progressed after standard front-line treatments. |
| How it is given or performed | AZD8205, alone or in combination with investigational agents, is administered intravenously in a closely monitored clinical trial setting; dosing schedules and combination partners are determined by sub-study and patient eligibility. | Current systemic therapies are typically delivered intravenously or orally, in cycles or ongoing as tolerated. Regimens, drug choice, and sequencing vary according to cancer type, prior treatments, and current guidelines. |
| Evidence status | Efficacy and safety are under investigation; no published clinical outcome data are available for AZD8205 in these cancers beyond early trial data and preclinical results. Mature anti-tumor data are lacking as of now. | Multiple large clinical trials, meta-analyses, and long-term observational studies support the anti-tumor benefit of current approved regimens for these cancers, with established median survival benefit and response rates per guidelines. |
| Important limitations | AZD8205 regimens are experimental; unknown clinical benefits and long-term risks; multi-arm design may not clarify superiority among regimens or versus standard care. Not all eligible cancers studied in each sub-study. Trial lacks a concurrent approved therapy control arm. | Standard therapies may not be effective after multiple prior treatment lines. Options may be limited by tumor resistance, prior toxicities, or co-morbidities. Benefits and tolerability can vary; not all patients will experience long-term control. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Variable depending on sub-study and dose levels
Participants receive AZD8205 alone or in combination with other anticancer agents to determine safe and tolerable doses.
Multiple visits as scheduled during treatment cycles
Duration - Up to approximately 2 years of treatment and assessment
Participants receive the recommended dose of AZD8205 or combinations to evaluate anti-tumor activity in selected solid tumors.
Regular visits for dosing, monitoring, and assessments
Duration - Up to 30 days post last dose and additional long-term assessments up to 2 years
Participants are monitored for safety and treatment outcomes after completing study treatment, including adverse events and survival.
Visits scheduled for safety checks and outcome measurements
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Yue Huang, Hui Yin Tan, Jiaqi Yuan...
https://pubmed.ncbi.nlm.nih.gov/39392424/AstraZeneca
Lead Sponsor